Shugo Sakihama1, Kazuho Morichika2, Megumi Miyara3, Takashi Miyagi4, Masaki Hayashi5, Junnosuke Uchihara6, Takeaki Tomoyose7, Sawako Nakachi2, Satoko Morishima2, Kazuko Sakai8, Kazuto Nishio8, Hiroaki Masuzaki2, Takuya Fukushima9, Kennosuke Karube1 (1.Pathol. and Cell Biol., Ryukyu Univ., Okinawa, Japan, 2.Second Department of Internal Medicine, Ryukyu Univ., Okinawa, Japan, 3.Health and Nutrition, Okinawa Univ., Okinawa, Japan, 4.Hemato., Heartlife Hosp., Okinawa, Japan, 5.Hemato., Nakagami Hosp., Okinawa, Japan, 6.Hematol., Naha-City Hosp., Okinawa, Japan, 7.Hematol., Okinawa Prefectural Nanbu Medical Center, Okinawa, Japan, 8.Genome Biol., Kindai Univ., Osaka, Japan, 9.Hematoimmunol., Ryukyu Univ., Okinawa, Japan)
Session information
Oral Session
Oral Session 2-10D ATL/HTLV-1: Molecular Mechanism/Therapeutic Target
Sat. Oct 12, 2019 4:00 PM - 5:00 PM No.10 (Tokyo International Forum, 4F G409)
Chair: Jun-ichirou Yasunaga (Laboratory of Virus Control, Institute for Frontier Life and Medical Sciences, Kyoto University)
Daisuke Kurita1, Junichiro Yasunaga1, Azusa Tanaka2, Masao Matsuoka3 (1.Frontier Life and Medical Sciences, Kyoto Univ., Kyoto, Japan, 2.Drug Discovery Med., Grad. Sch. Med., Kyoto Univ., Kyoto, Japan, 3.Dept. of Hemat. Rheumat. Infect. Disease, Kumamoto Univ., Kumamoto, Japan)
Yusuke Higuchi1,2, Junichiro Yasunaga1, Yu Mitagami1, Koichi Ohshima3, Masao Matsuoka1,2 (1.Institute for Frontier Life and Medical Sciences, Kyoto University, Japan, 2.Departments of Hematology, Rheumatology and Infectious Disease, Kumamoto University, Japan, 3.Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan)
Tatsuro Watanabe1, Hiroshi Ureshino1, Kazuharu Kamachi1,2, Yuki Kurahashi1,3, Yuki Kurahashi1,3, Satoshi Yamashita4, Seiji Okada5, Toshikazu Ushijima4, Eisaburo Sueoka6, Shinya Kimura1,2 (1.Drug Discov. and Biomed. Sci., Saga Univ., Saga, Japan, 2.Dept. Hematology, Respiratory Medicine and Oncology, Saga Univ., Saga, Japan, 3.OHARA Pharmaceutical Co., Ltd., Shiga, Japan, 4.Div. Epigenomics, Natl. Cancer Ctr. Res. Inst., Tokyo, Japan, 5.Div. Hematopoiesis, Joint Res. Ctr. Human Retrovirus Infection, Kumamoto, Japan, 6.Dept. Clin. Lab. Med., Saga Univ., Saga, Japan)
Tomonaga Ichikawa1, Obeid Shanab1, Shingo Nakahata1, Masaya Ono2, Hidekatsu Iha3, Kazuhiro Morishita1 (1.Tumor and Cellular Biochemistry, University of Miyazaki, 2.National Cancer Center Research Institute, 3.Microbiology, University of Oita)
Naoki Mori1, Chie Ishikawa1,2 (1.Dept. Microbiol. Oncol., Univ. of the Ryukyus, Okinawa, Japan, 2.Transdisciplinary Res. Organ. Subtrop. Isl. Stud., Univ. of the Ryukyus, Okinawa, Japan)